Gene News and Research

Latest Gene News and Research

RXi Pharmaceuticals reports positive results from second Phase 1 study with RXI‑109

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor, and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.

12 Jul 2013

International team explores genetic diversity of Plasmodium vivax in the Americas

Human migrations - from the prehistoric epoch to the present day - have extended cultures across the globe. With these travelers have come unwanted stowaways: mosquito-borne parasites belonging to the Plasmodium species - a group responsible for malaria, worldwide.

12 Jul 2013

Scientists discover chain of molecular mechanisms set in motion by glucocorticoids

These scientists under the leadership of Martin Bilban from the Clinical Institute of Laboratory Medicine at the MedUni Vienna discovered a chain of molecular mechanisms, which is kick-started by the formation of glucocorticoids.

12 Jul 2013

Genome sequencing promises to identify rare mutations that give rise to autism

An international consortium, consisting of Autism Speaks, Duke University School of Medicine, The Hospital for Sick Children of Toronto, BGI and other institutes, has investigated the genetic variants in 32 families with Autism Spectrum Disorder (ASD).

12 Jul 2013

Seven scientists to receive Annual Klerman and Freedman Prizes from Brain & Behavior Research Foundation

Seven young scientists will be recognized by the Brain & Behavior Research Foundation at its presentation of the Annual Klerman and Freedman Prizes on Friday July 26, 2013 at Le Parker Meriden Hotel, New York, NY.

12 Jul 2013

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis.

12 Jul 2013

Seven named recipients of GSA poster awards at 19th International C. elegans Meeting

Six graduate students and one undergraduate were named as recipients of Genetics Society of America poster awards at the 19th International C. elegans Meeting, held June 26 on the campus of the University of California, Los Angeles.

12 Jul 2013

Researchers identify receptor mutation that blocked estrogen action in young woman

A receptor mutation that essentially blocks estrogen's action has been identified for the first time a female, researchers report.

12 Jul 2013

Hydrogel method form synthetic scaffolds to support formation of blood vessels in engineered tissues

Next-generation hydrogels can form synthetic scaffolds to support the formation of replacement tissues and organs in the emerging area of regenerative medicine. Embedding peptides into the hydrogels stimulates the growth of essential microvascular networks to ensure a good blood supply.

12 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

ELSIP: Integrating personalized medicine into clinical practice

Lynn G. Dressler Dr. P.H. Director, Personalized Medicine and Pharmacogenomics, Mission Health, Fullerton Genetics Center will present: Addressing the Ethical, Legal, Social and Policy Issues Related to Integrating Personalized Medicine into Routine Clinical Care at the 5th Annual Personalized Medicine Conference in Boston, MA on October 21- 22, 2013.

11 Jul 2013

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

Linda Watkins, Ph.D., Distinguished Professor, Department of Psychology & Neuroscience and Center for Neuroscience, University of Colorado, Co-Chair, Advisory Board, Xalud Therapeutics, Inc. will present research on activating Glial Cells as part of the speaking faculty at the 7th Annual Pain Therapeutics Summit East in Boston, MA.

11 Jul 2013

Protein used by cancer cells also plays a vital role in heart health

St. Jude Children's Research Hospital scientists have discovered that a protein used by cancer cells to evade death also plays a vital role in heart health. This dual role complicates efforts to develop cancer drugs that target the protein, but may lead to new therapies for heart muscle damage. The research appeared in the June 15 edition of the scientific journal Genes & Development.

11 Jul 2013

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Pharmacyclics, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for the investigational oral Bruton's tyrosine kinase inhibitor, ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

10 Jul 2013

Children born after assisted reproduction at no greater risk for cancer, study finds

Children born as a result of assisted reproduction are at no greater risk of cancer than children born spontaneously in the general population, according to results of one of the largest ever cohort studies of ART children.

10 Jul 2013

Study confirms role of MAPK mutations in pilocytic astrocytomas

Brain cancer is the primary cause of cancer mortality in children. Even in cases when the cancer is cured, young patients suffer from the stress of a treatment that can be harmful to the developing brain. In a search for new target structures that would create more gentle treatments, cancer researchers are systematically analyzing all alterations in the genetic material of these tumors.

10 Jul 2013

New approach delivers RNA drugs to silence malfunctioning genes

Silencing genes that have malfunctioned is an important approach for treating diseases such as cancer and heart disease. One effective approach is to deliver drugs made from small molecules of ribonucleic acid, or RNA, which are used to inhibit gene expression. The drugs, in essence, mimic a natural process called RNA interference.

10 Jul 2013

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Study shows disrupted micronuclei may prove to be a valuable tool for detecting cancer

Scientists studying cancer development have known about micronuclei for some time. These erratic, small extra nuclei, which contain fragments or whole chromosomes that were not incorporated into daughter cells after cell division, are associated with specific forms of cancer and are predictive of poorer prognosis.

10 Jul 2013

Low vitamin D blood levels associated with greater risk of heart disease varies by race, ethnicity

Low vitamin D blood levels are linked to greater risk of heart disease in whites and Chinese, but not in blacks and Hispanics, according to a study appearing this week in JAMA, a journal published by the American Medical Association.

10 Jul 2013

Gene News and Research

Latest Gene News and Research

RXi Pharmaceuticals reports positive results from second Phase 1 study with RXI‑109

International team explores genetic diversity of Plasmodium vivax in the Americas

Scientists discover chain of molecular mechanisms set in motion by glucocorticoids

Genome sequencing promises to identify rare mutations that give rise to autism

Seven scientists to receive Annual Klerman and Freedman Prizes from Brain & Behavior Research Foundation

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Seven named recipients of GSA poster awards at 19th International C. elegans Meeting

Researchers identify receptor mutation that blocked estrogen action in young woman

Hydrogel method form synthetic scaffolds to support formation of blood vessels in engineered tissues

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

ELSIP: Integrating personalized medicine into clinical practice

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

Protein used by cancer cells also plays a vital role in heart health

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Children born after assisted reproduction at no greater risk for cancer, study finds

Study confirms role of MAPK mutations in pilocytic astrocytomas

New approach delivers RNA drugs to silence malfunctioning genes

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Study shows disrupted micronuclei may prove to be a valuable tool for detecting cancer

Low vitamin D blood levels associated with greater risk of heart disease varies by race, ethnicity

Industry Focus: Cell & Gene Therapy eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?